Deals Shaping The Medical Industry, July-August 2012
Executive Summary
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
Refillable Personal-Care Packaging: Experts Discuss Contamination Risks, Liability, MoCRA Compliance
Personal-care companies navigating a growing patchwork of state recycling laws are exploring refillable packaging options, but there are serious concerns and questions to consider before embarking down this potentially risky path, experts said at IBA’s Supply Chain & Sustainability Conference.
Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment
The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.
Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?
Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.